Pharma
Aurobindo Pharma Ltd
AUROPHARMA · NSE · INE406A01037Vol: 11.9L traded · 49.8% delivered
Market Cap—
P/E26.3
P/B2.6
EPS₹64
Div Yield0.3%
ROE9.9%
ROCE12.7%
ROE9.9%
1Y Return+50.72%
Avg. Volume0.8M
Delivery %49.79%
Price Chart
About
Aurobindo Pharma Ltd is a Pharma company listed on NSE.
Technicals
Free account
Register freeTechnicals
Create a free account to view momentum, moving averages, and delivery signals.
Quant
Premium
UpgradeQuant metrics
Upgrade to view volatility, drawdown, factor, and risk metrics.
Key Ratios
Market Cap—
Current Price—
52W High / Low—
Stock P/E26.3
Price to Book2.6
EPS (TTM)₹64
Dividend Yield0.3%
ROE9.9%
1Y Return+50.72%
Day Change—
Profit & Loss
| Period | TTM | FY26 | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | ₹34,935 Cr | ₹33,653 Cr | ₹31,724 Cr | ||||||||||
| Expenses | ₹27,854 Cr | ₹26,783 Cr | ₹25,164 Cr | ||||||||||
| Operating Profit | ₹7,081 Cr | ₹6,870 Cr | ₹6,560 Cr | ||||||||||
| OPM % | 20.0% | 20.0% | 21.0% | ||||||||||
| Other Income | ₹586 Cr | ₹404 Cr | ₹613 Cr | ||||||||||
| Depreciation | ₹1,859 Cr | ₹1,778 Cr | ₹1,649 Cr | ||||||||||
| Interest | ₹388 Cr | ₹384 Cr | ₹457 Cr | ||||||||||
| Profit Before Tax | ₹5,420 Cr | ₹5,112 Cr | ₹5,066 Cr | ||||||||||
| Tax | ₹1,709 Cr | ₹1,609 Cr | ₹1,582 Cr | ||||||||||
| Net Profit | ₹3,711 Cr | ₹3,503 Cr | ₹3,484 Cr | ||||||||||
| EPS (₹) | 64.1 | 60.3 | 60.0 | ||||||||||
| Dividend Payout % | — | 7% | 0% |
Financial history locked
Register freeRegister free to see 10 more years.
Quarterly Results
| Quarter | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | ₹9,150 Cr | ₹8,853 Cr | ₹8,646 Cr | ₹8,286 Cr | |||||||||
| Expenses | ₹7,271 Cr | ₹7,103 Cr | ₹6,873 Cr | ₹6,608 Cr | |||||||||
| Operating Profit | ₹1,880 Cr | ₹1,750 Cr | ₹1,773 Cr | ₹1,678 Cr | |||||||||
| OPM % | 21.0% | 20.0% | 21.0% | 20.0% | |||||||||
| Depreciation | ₹487 Cr | ₹479 Cr | ₹465 Cr | ₹429 Cr | |||||||||
| Interest | ₹102 Cr | ₹98 Cr | ₹93 Cr | ₹95 Cr | |||||||||
| Net Profit | ₹1,032 Cr | ₹921 Cr | ₹910 Cr | ₹848 Cr | |||||||||
| EPS (₹) | 18.0 | 15.9 | 15.7 | 14.6 |
Quarterly history locked
Register freeRegister free to see 9 more quarters.
Balance Sheet
| Period | FY26 | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Equity Capital | ₹58 Cr | ₹58 Cr | ₹59 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reserves | ₹37,833 Cr | ₹32,595 Cr | ₹29,784 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Borrowings | ₹8,073 Cr | ₹8,263 Cr | ₹6,648 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Liabilities | ₹12,232 Cr | ₹8,566 Cr | ₹8,226 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Liabilities | ₹58,196 Cr | ₹49,482 Cr | ₹44,717 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assets | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fixed Assets | ₹17,407 Cr | ₹14,794 Cr | ₹14,493 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Investments | ₹1,051 Cr | ₹252 Cr | ₹372 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Receivables | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventory | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cash & Equivalents | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Assets | ₹34,525 Cr | ₹29,536 Cr | ₹25,983 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Assets | ₹58,196 Cr | ₹49,482 Cr | ₹44,717 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Balance sheet history locked
Register freeRegister free to see 10 more years.
Cash Flow
| Period | Operating | Investing | Financing | Net Cash Flow |
|---|---|---|---|---|
| FY26 | ₹5,526 Cr | ₹-2,630 Cr | ₹-1,269 Cr | ₹1,628 Cr |
| FY25 | ₹3,925 Cr | ₹-1,866 Cr | ₹120 Cr | ₹2,178 Cr |
| FY24 | ₹2,435 Cr | ₹-4,242 Cr | ₹800 Cr | ₹-1,007 Cr |
| FY23 | ||||
| FY22 | ||||
| FY21 | ||||
| FY20 | ||||
| FY19 | ||||
| FY18 | ||||
| FY17 | ||||
| FY16 | ||||
| FY15 |
Cash flow history locked
Register freeRegister free to see 10 more years.
Peer Comparison
| Company | M.Cap | P/E | ROE | 1Y Return |
|---|---|---|---|---|
| 3B BlackBio Dx Ltd | ₹1,210 Cr | 21.4 | +20.2% | +17.9% |
| Aarey Drugs & Pharmaceuticals Ltd | ₹353 Cr | 75.3 | +2.75% | +59.84% |
| Aarti Drugs Ltd | ₹3,429 Cr | 18.0 | +13.37% | +11.57% |
| Aarti Pharmalabs Ltd | ₹7,495 Cr | 35.2 | +8.51% | +14.26% |
| Abbott India Ltd | — | — | +34.46% | -7.16% |
Mutual Fund Holdings
Free account
Register freeMutual fund holdings
Create a free account to see institutional ownership snapshots.
Bulk & Block Deals
Free account
Register freeBulk & block deals
Create a free account to view recent institutional deal activity.
Analyst Estimates
Free account
Register freeAnalyst estimates
Create a free account to view analyst estimate summaries.
Latest News
2026-10-09Announcement under Regulation 30 (LODR)-Newspaper PublicationBSE Filing2026-08-06Aurobindo Pharma Ltd (BOM:524804) (Q1 2027) Earnings Call Highlights: Record Revenue Growth and ...GuruFocus.com2026-08-05What to Expect From Aurobindo Pharma Ltd (NSE:AUROPHARMA) Q1 2027 EarningsGuruFocus.com
Documents & Filings
rupiya.io is for research and education only. Metrics shown are not investment advice. Validate with SEBI-regulated disclosures before acting.